Abstract 600P
Background
The standard neoadjuvant therapy for locally advanced rectal cancer (LARC) is chemoradiotherapy (CRT) which increases perioperative complications. Chemotherapy alone has approximately 60% objective response rate and lower pathological complete response pCR rate compare with CRT. We propose a new strategy (induction chemotherapy followed by arterial infusion chemotherapy and anti-PD1 antibody) to achieve high pCR rate for microsatellite stable (MSS) LARC without radiotherapy.
Methods
Two cycles of Capox were given to eligible LARC patients (tumor located 5-12cm from anal verge). Patients who achieved more than 20% regression of maximum tumor diameter receive 2 cycles of rectal arterial infusion oxaliplatin (50mg, D1) + intravenous anti-PD1 inhibitor (Sintilimab, 200mg, D2) + capecitabine (1000mg/m2, po, twice daily, D1-D14) with 6 weeks before operation. Patients with tumor regression less than 20% were suggested to receive CRT. The primary endpoint is pCR rate. A total of 38 patients (10 in the first stage, 28 in the second) stage are planned to be recruited by Simon’s two-stage design. The second stage will be conducted if more than 2 patients achieve pCR in the first stage, otherwise the trial will be terminated.
Results
A total of 20 patients had been enrolled and 13/20 reached 20% regression criterion after induction chemotherapy and received arterial infusion chemotherapy combined with intravenous anti-PD1 antibody. One patient achieved clinical complete response and refused surgery. Other 12 patients received operation and 4/12 (33.3%) achieved pCR (3/10 in the first stage). According to the tumor regression grading TRGstandard of the eighth edition of AJCC, the patients number of TRG0/1/2/3 was 4/4/2/2, respectively. Among the 12 patients 5 had grade 3 adverse event (abdominal pain and readmission), including one grade 3 immune-related adverse event (dermatitis).
Conclusions
Rectal arterial infusion chemotherapy combined with intravenous anti-PD1 antibody for MSS LARC achieved high pCR rate. The RAIC trial is now progressed to the second stage.
Clinical trial identification
NCT05307198.
Editorial acknowledgement
Legal entity responsible for the study
The Second Affiliated Hospital Zhejiang University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10